Cytognosis Foundation—a 501(c)(3) nonprofit healthcare moonshot at the intersection of science, technology, and humanity—is dedicated to transforming global healthcare through AI-native technologies that enable early detection and prevention of disease.
Transforming lives before disease defines them.
A world where predictive health is a fundamental human right, not a privilege.
Democratize cellular intelligence that detects disease at the molecular level years before symptoms emerge.
Save millions of lives by making personalized health monitoring universally accessible—regardless of geography, income, gender, or ethnicity.
A comprehensive AI platform that integrates multimodal data to create personalized health profiles, enabling early detection of disease risk factors and providing actionable insights for preventive interventions.
An advanced diagnostic tool that uses AI to analyze biological samples with unprecedented precision, identifying subtle cellular changes that may indicate disease development long before clinical symptoms appear.
A revolutionary preventive intervention system that delivers personalized recommendations and treatments based on individual health profiles, effectively addressing disease risk factors before they progress to clinical conditions.
A 15-year roadmap to transform global healthcare
Building our core AI-native technologies through rigorous research and development, establishing partnerships with leading academic and healthcare institutions, and conducting initial validation studies.
Scaling our technologies for broader implementation, securing regulatory approvals, establishing strategic partnerships with healthcare providers, and developing sustainable revenue models to support our nonprofit mission.
Expanding access to our technologies worldwide with a focus on underserved populations, adapting solutions for diverse healthcare systems, and working with international organizations to address global health disparities.
5-10 years
Earlier disease detection compared to conventional methods
60-80%
Potential reduction in treatment costs through early intervention
100+
Target countries for technology deployment